76 related articles for article (PubMed ID: 17239341)
1. Dermatan sulfate inhibits osteoclast formation by binding to receptor activator of NF-kappa B ligand.
Shinmyouzu K; Takahashi T; Ariyoshi W; Ichimiya H; Kanzaki S; Nishihara T
Biochem Biophys Res Commun; 2007 Mar; 354(2):447-52. PubMed ID: 17239341
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor regulates osteoclast differentiation and survival through cross-talking with RANK signaling.
Yi T; Lee HL; Cha JH; Ko SI; Kim HJ; Shin HI; Woo KM; Ryoo HM; Kim GS; Baek JH
J Cell Physiol; 2008 Nov; 217(2):409-22. PubMed ID: 18543257
[TBL] [Abstract][Full Text] [Related]
3. Suramin interacts with RANK and inhibits RANKL-induced osteoclast differentiation.
Regmi A; Fuson T; Yang X; Kays J; Moxham C; Zartler E; Chandrashekhar S; Galvin RJ
Bone; 2005 Feb; 36(2):284-91. PubMed ID: 15780954
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms involved in the enhancement of osteoclast formation by enamel matrix derivative.
Itoh N; Kasai H; Ariyoshi W; Harada E; Yokota M; Nishihara T
J Periodontal Res; 2006 Aug; 41(4):273-9. PubMed ID: 16827720
[TBL] [Abstract][Full Text] [Related]
5. Receptor activator of nuclear factor-kappaB ligand-induced mouse osteoclast differentiation is associated with switching between NADPH oxidase homologues.
Sasaki H; Yamamoto H; Tominaga K; Masuda K; Kawai T; Teshima-Kondo S; Matsuno K; Yabe-Nishimura C; Rokutan K
Free Radic Biol Med; 2009 Jul; 47(2):189-99. PubMed ID: 19409483
[TBL] [Abstract][Full Text] [Related]
6. Paeonol inhibits RANKL-induced osteoclastogenesis by inhibiting ERK, p38 and NF-kappaB pathway.
Tsai HY; Lin HY; Fong YC; Wu JB; Chen YF; Tsuzuki M; Tang CH
Eur J Pharmacol; 2008 Jun; 588(1):124-33. PubMed ID: 18495114
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of osteoclast differentiation by polycyclic aryl hydrocarbons is dependent on cell density and RANKL concentration.
Voronov I; Heersche JN; Casper RF; Tenenbaum HC; Manolson MF
Biochem Pharmacol; 2005 Jul; 70(2):300-7. PubMed ID: 15919055
[TBL] [Abstract][Full Text] [Related]
8. Receptor activator of NF-kappaB ligand induces the expression of carbonic anhydrase II, cathepsin K, and matrix metalloproteinase-9 in osteoclast precursor RAW264.7 cells.
Fujisaki K; Tanabe N; Suzuki N; Kawato T; Takeichi O; Tsuzukibashi O; Makimura M; Ito K; Maeno M
Life Sci; 2007 Mar; 80(14):1311-8. PubMed ID: 17306833
[TBL] [Abstract][Full Text] [Related]
9. The 4-1BB ligand and 4-1BB expressed on osteoclast precursors enhance RANKL-induced osteoclastogenesis via bi-directional signaling.
Yang J; Park OJ; Lee YJ; Jung HM; Woo KM; Choi Y
Eur J Immunol; 2008 Jun; 38(6):1598-609. PubMed ID: 18421790
[TBL] [Abstract][Full Text] [Related]
10. Hyaluronan inhibits osteoclast differentiation via Toll-like receptor 4.
Chang EJ; Kim HJ; Ha J; Kim HJ; Ryu J; Park KH; Kim UH; Lee ZH; Kim HM; Fisher DE; Kim HH
J Cell Sci; 2007 Jan; 120(Pt 1):166-76. PubMed ID: 17164294
[TBL] [Abstract][Full Text] [Related]
11. A novel PPARgamma agonist, KR62776, suppresses RANKL-induced osteoclast differentiation and activity by inhibiting MAP kinase pathways.
Park JY; Bae MA; Cheon HG; Kim SS; Hong JM; Kim TH; Choi JY; Kim SH; Lim J; Choi CH; Shin HI; Kim SY; Park EK
Biochem Biophys Res Commun; 2009 Jan; 378(3):645-9. PubMed ID: 19059209
[TBL] [Abstract][Full Text] [Related]
12. NF-kappaB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANKL, osteoprotegerin or macrophage colony-stimulating factor.
Kubota T; Hoshino M; Aoki K; Ohya K; Komano Y; Nanki T; Miyasaka N; Umezawa K
Arthritis Res Ther; 2007; 9(5):R97. PubMed ID: 17892600
[TBL] [Abstract][Full Text] [Related]
13. Baicalein inhibits osteoclast differentiation and induces mature osteoclast apoptosis.
Kim MH; Ryu SY; Bae MA; Choi JS; Min YK; Kim SH
Food Chem Toxicol; 2008 Nov; 46(11):3375-82. PubMed ID: 18786594
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of RANK/RANKL signal transduction pathway: a promising approach for osteoporosis treatment.
Bai YD; Yang FS; Xuan K; Bai YX; Wu BL
Med Hypotheses; 2008 Aug; 71(2):256-8. PubMed ID: 18445511
[TBL] [Abstract][Full Text] [Related]
15. Receptor activator of nuclear factor-kappa B ligand induces osteoclast formation in RAW 264.7 macrophage cells via augmented production of macrophage-colony-stimulating factor.
Islam S; Hassan F; Tumurkhuu G; Dagvadorj J; Koide N; Naiki Y; Yoshida T; Yokochi T
Microbiol Immunol; 2008 Dec; 52(12):585-90. PubMed ID: 19120972
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effect of (-)-saucerneol on osteoclast differentiation and bone pit formation.
Kim SN; Kim MH; Kim YS; Ryu SY; Min YK; Kim SH
Phytother Res; 2009 Feb; 23(2):185-91. PubMed ID: 18690659
[TBL] [Abstract][Full Text] [Related]
17. Berberine inhibits RANKL-induced osteoclast formation and survival through suppressing the NF-kappaB and Akt pathways.
Hu JP; Nishishita K; Sakai E; Yoshida H; Kato Y; Tsukuba T; Okamoto K
Eur J Pharmacol; 2008 Feb; 580(1-2):70-9. PubMed ID: 18083161
[TBL] [Abstract][Full Text] [Related]
18. The mechanism of osteoclast differentiation induced by IL-1.
Kim JH; Jin HM; Kim K; Song I; Youn BU; Matsuo K; Kim N
J Immunol; 2009 Aug; 183(3):1862-70. PubMed ID: 19587010
[TBL] [Abstract][Full Text] [Related]
19. Activated platelets positively regulate RANKL-mediated osteoclast differentiation.
Weicht B; Maitz P; Kandler B; Fischer MB; Watzek G; Gruber R
J Cell Biochem; 2007 Dec; 102(5):1300-7. PubMed ID: 17957725
[TBL] [Abstract][Full Text] [Related]
20. Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK.
Théoleyre S; Kwan Tat S; Vusio P; Blanchard F; Gallagher J; Ricard-Blum S; Fortun Y; Padrines M; Rédini F; Heymann D
Biochem Biophys Res Commun; 2006 Aug; 347(2):460-7. PubMed ID: 16828054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
